200 related articles for article (PubMed ID: 31974712)
1. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology.
Blum Murphy M; Ikoma N; Wang X; Estrella J; Roy-Chowdhuri S; Das P; Minsky BD; Song S; Mansfield P; Ajani J; Badgwell B
Ann Surg Oncol; 2020 Aug; 27(8):2806-2811. PubMed ID: 31974712
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma.
Badgwell B; Blum M; Das P; Estrella J; Wang X; Ho L; Fournier K; Royal R; Mansfield P; Ajani J
Ann Surg Oncol; 2017 Oct; 24(11):3338-3344. PubMed ID: 28799004
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology.
Badgwell B; Ikoma N; Murphy MB; Wang X; Estrella J; Roy-Chowdhuri S; Das P; Minsky BD; Lano E; Song S; Mansfield P; Ajani J
Ann Surg Oncol; 2021 Jan; 28(1):258-264. PubMed ID: 32556731
[TBL] [Abstract][Full Text] [Related]
4. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy.
Newhook TE; Agnes A; Blum M; Estrella JS; Das P; Ho L; Ajani JA; Minsky BD; Mansfield P; Badgwell BD
Ann Surg Oncol; 2019 May; 26(5):1394-1400. PubMed ID: 30680477
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
Yang XJ; Huang CQ; Suo T; Mei LJ; Yang GL; Cheng FL; Zhou YF; Xiong B; Yonemura Y; Li Y
Ann Surg Oncol; 2011 Jun; 18(6):1575-81. PubMed ID: 21431408
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
7. Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial.
Wu MF; Cheng XY; Wang DY; Lai YT; Li H; Ye YF; Peng YP; Chen Q; Zhang BZ; Lin ZQ; Li J
Gynecol Oncol; 2024 Feb; 181():125-132. PubMed ID: 38159362
[TBL] [Abstract][Full Text] [Related]
8. Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations.
Pelz JO; Doerfer J; Dimmler A; Hohenberger W; Meyer T
BMC Cancer; 2006 Jun; 6():162. PubMed ID: 16792796
[TBL] [Abstract][Full Text] [Related]
9. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Hakeam HA; Arab A; Azzam A; Alyahya Z; Eldali AM; Amin T
Cancer Chemother Pharmacol; 2018 Apr; 81(4):697-704. PubMed ID: 29429054
[TBL] [Abstract][Full Text] [Related]
10. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer.
Badgwell B; Blum M; Das P; Estrella J; Wang X; Fournier K; Royal R; Mansfield P; Ajani J
Surg Endosc; 2018 Jan; 32(1):512. PubMed ID: 28643069
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
[TBL] [Abstract][Full Text] [Related]
13. Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Cotte E; Passot G; Tod M; Bakrin N; Gilly FN; Steghens A; Mohamed F; Glehen O
Ann Surg Oncol; 2011 Sep; 18(9):2599-603. PubMed ID: 21424369
[TBL] [Abstract][Full Text] [Related]
14. Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results.
van der Kaaij RT; Wassenaar ECE; Koemans WJ; Sikorska K; Grootscholten C; Los M; Huitema A; Schellens JHM; Veenhof AAFA; Hartemink KJ; Aalbers AGJ; van Ramshorst B; Boerma D; Boot H; van Sandick JW
Br J Surg; 2020 Oct; 107(11):1520-1528. PubMed ID: 32277764
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
Sun JH; Ji ZH; Peng KW; Wu HT; Zhang Q; Yonemura Y; Li Y
Int J Hyperthermia; 2016 May; 32(3):289-97. PubMed ID: 26982735
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
17. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
18. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
19. Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
Chia CS; You B; Decullier E; Vaudoyer D; Lorimier G; Abboud K; Bereder JM; Arvieux C; Boschetti G; Glehen O;
Ann Surg Oncol; 2016 Jun; 23(6):1971-9. PubMed ID: 26753751
[TBL] [Abstract][Full Text] [Related]
20. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Somashekhar SP; Yethadka R; Kumar C R; Ashwin KR; Zaveri S; Rauthan A
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):577-581. PubMed ID: 31677939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
